Galectin 3 Binding Protein as a biomarker of choledochal cyst in children: A pilot study
DOI:
https://doi.org/10.46831/jpas.v2i1.144Keywords:
Galectin-3-binding protein, Choledochal cyst, Serological biomarkerAbstract
A choledochal cyst (CDC) is a rare congenital, single, or multiple cystic dilatations of the biliary tract encountered most commonly in infants and children. A sensitive and specific serological marker, if available, may add to its early recognition thereby avoiding the risk of complications frequently seen in these patients. We analyzed serum galectin-3-binding protein (Gal-3BP) levels in 21 children with CDC and 14 age-matched controls by the ELISA method. Serum Gal-3-BP levels were significantly raised in the patient group (36.6 ±25.2 ng/ml versus 7.0 ±4.3 ng/ml in controls; p <0.0001) and 95.2% of patients had Gal-3BP levels higher than the mean value in controls. Almost 67% of patients showed values ≥3 times of mean Gal-3BP level in controls (p <0.0001). Equal to 5 times or greater levels were seen in 43% of the patients (p = 0.0051). The study, therefore, suggests further evaluation of Gal-3BP as a potential biomarker for CDC and other biliary disorders.
Downloads
Metrics
References
Cha SW, Park MS, Kim KW, Byun JH, Yu JS, Kim MJ, et al. Choledochal cyst and anomalous pancreaticobiliary ductal union in adults: Radiological spectrum and complications. Vol. 32, Journal of Computer Assisted Tomography. 2008.
Soares KC, Arnaoutakis DJ, Kamel I, Rastegar N, Anders R, Maithel S, et al. Choledochal cysts: Presentation, clinical differentiation, and management. Vol. 219, Journal of the American College of Surgeons. 2014.
Ming G, Guo W, Cheng Y, Wang J. Identification and evaluation of fructose-bisphosphate aldolase B as a potential diagnostic biomarker in choledochal cysts patients: A quantitative proteomic analysis. Translational Pediatrics. 2021;10(8).
Koths K, Taylor E, Halenbeck R, Casipit C, Wang A. Cloning and characterization of a human Mac-2-binding protein, a new member of the superfamily defined by the macrophage scavenger receptor cysteine-rich domain. Journal of Biological Chemistry. 1993;268(19).
Capone E, Iacobelli S, Sala G. Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target. Vol. 19, Journal of Translational Medicine. 2021.
DeRoo EP, Wrobleski SK, Shea EM, Al-Khalil RK, Hawley AE, Henke PK, et al. The role of galectin-3 and galectin-3-binding protein in venous thrombosis. Blood. 2015;125(11).
Hara A, Niwa M, Noguchi K, Kanayama T, Niwa A, Matsuo M, et al. Galectin-3 as a next-generation biomarker for detecting early stages of various diseases. Vol. 10, Biomolecules. 2020.
Tamaki N, Higuchi M, Kurosaki M, Kirino S, Osawa L, Watakabe K, et al. Wisteria floribunda agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver disease. Scientific Reports. 2019;9(1).
Sugiura T, Dohi Y, Takase H, Yamashita S, Murai S, Tsuzuki Y, et al. Serum levels of Mac-2 binding protein increase with cardiovascular risk and reflect silent atherosclerosis. Atherosclerosis. 2016;251.
Gleissner CA, Erbel C, Linden F, Domschke G, Akhavanpoor M, Helmes CM, et al. Galectin-3 binding protein, coronary artery disease and cardiovascular mortality: Insights from the LURIC study. Atherosclerosis. 2017;260.
Zhen S, Ma Y, Han Y, Zhao Z, Yang X, Wen D. Serum galectin-3BP as a novel marker of obesity and metabolic syndrome in Chinese adolescents. BMJ Open Diabetes Research and Care. 2021;9(1).
Rana R, Chauhan K, Gautam P, Kulkarni M, Banerjee R, Chugh P, et al. Plasma-Derived Extracellular Vesicles Reveal Galectin-3 Binding Protein as Potential Biomarker for Early Detection of Glioma. Frontiers in Oncology. 2021;11.
Singham J, Yoshida EM, Scudamore CH. Choledochal cysts: part 2 of 3: Diagnosis. Canadian journal of surgery Journal canadien de chirurgie. 2009;52(6).
Iacovazzi PA, Trisolini A, Barletta D, Elba S, Manghisi OG, Correale M. Serum 90K/MAC-2BP glycoprotein in patients with liver cirrhosis and hepatocellular carcinoma: A comparison with α-fetoprotein. Clinical Chemistry and Laboratory Medicine. 2001;39(10).
Kamada Y, Fujii H, Fujii H, Sawai Y, Doi Y, Uozumi N, et al. Serum Mac-2 binding protein levels as a novel diagnostic biomarker for prediction of disease severity and nonalcoholic steatohepatitis. Proteomics - Clinical Applications. 2013;7(9–10).
Kamada Y, Morishita K, Koseki M, Nishida M, Asuka T, Naito Y, et al. Serum mac-2 binding protein levels associate with metabolic parameters and predict liver fibrosis progression in subjects with fatty liver disease: A 7-year longitudinal study. Nutrients. 2020;12(6).
Cheung KJ, Tilleman K, Deforce D, Colle I, van Vlierberghe H. The HCV serum proteome: A search for fibrosis protein markers. Journal of Viral Hepatitis. 2009;16(6).
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Anil Kumar Ram, Yashwant Kumar, Prema Menon, Ravi Prakash Kanojia, Alka Bhatia, Ranjana Walker Minz
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
